In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy

Hirokazu Okada(Kyoto University), Hiroshi Seno(Kyoto University)
Scientific Reports
February 8, 2022
Cited by 18


Related Papers